CenterBook Partners LP lessened its stake in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 27.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 124,054 shares of the company’s stock after selling 46,175 shares during the period. CenterBook Partners LP’s holdings in Progyny were worth $3,125,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. Oregon Public Employees Retirement Fund lifted its stake in shares of Progyny by 4.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock valued at $435,000 after acquiring an additional 700 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Progyny during the 3rd quarter valued at about $278,000. Summit Global Investments bought a new position in shares of Progyny in the 3rd quarter valued at about $1,105,000. State of Wyoming boosted its stake in shares of Progyny by 3.5% in the 3rd quarter. State of Wyoming now owns 29,806 shares of the company’s stock valued at $751,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its stake in shares of Progyny by 17.0% in the 3rd quarter. Sterling Capital Management LLC now owns 15,068 shares of the company’s stock valued at $380,000 after purchasing an additional 2,191 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.
More Progyny News
Here are the key news stories impacting Progyny this week:
- Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
- Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
- Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
- Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on PGNY. BTIG Research lifted their price target on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Wells Fargo & Company increased their price objective on shares of Progyny from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday. Citizens Jmp raised their price objective on shares of Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a research note on Thursday. Truist Financial raised their price objective on shares of Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Finally, Wall Street Zen raised shares of Progyny from a “buy” rating to a “strong-buy” rating in a report on Sunday. Eleven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.92.
View Our Latest Report on Progyny
Progyny Trading Up 1.4%
NASDAQ PGNY opened at $34.84 on Friday. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $35.50. The stock has a 50-day simple moving average of $27.45 and a 200 day simple moving average of $24.59. The company has a market capitalization of $2.67 billion, a PE ratio of 31.96, a P/E/G ratio of 2.40 and a beta of 0.97.
Progyny (NASDAQ:PGNY – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.21. The business had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same period last year, the business earned $0.15 earnings per share. As a group, sell-side analysts predict that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CFO Mark Livingston sold 2,139 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total value of $64,170.00. Following the transaction, the chief financial officer owned 70,314 shares in the company, valued at approximately $2,109,420. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa Cummings sold 1,879 shares of the business’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer directly owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 19,421 shares of company stock valued at $539,960. Company insiders own 9.90% of the company’s stock.
About Progyny
Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.
Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.
Progyny primarily serves self-insured employers and their employees in the United States.
Featured Stories
- Five stocks we like better than Progyny
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
